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Crohn disease (CD) and ulcerative colitis (UC) are overlapping chronic inflammatory bowel diseases (IBDs). Suggestive
evidence for linkage at chromosome 7q has been reported for both CD and UC. Contained within this region is the
gene for MDR1 (multidrug resistance), a membrane transport protein for which human polymorphisms have been
reported in Ala893Ser/Thr and C3435T that alter pharmacokinetic profiles for a variety of drugs. Because mdr1
knockout mice spontaneously develop colitis, exonic regions were resequenced and tested for IBD association in
a large, multicenter North American cohort. Two missense mutations, Asn21Asp and Ala893Ser/Thr, as well as
the expression-associated polymorphism C3435T, described elsewhere, were genotyped in the entire cohort. Sig-
nificant association of Ala893 with IBD was observed by both case-control analysis ( ) and the pedigreePp .002
disequilibrium test (PDT [ ]) but not for the Asn21Asp or C3435T polymorphisms. SignificantPp .00020–.00030
association by PDT was observed within the subset with CD ( ), with similar, nonsignificantPp .0014–.00090
trends in a smaller subset with UC. The Ala893Ser/Thr variant is triallelic, and the associated, common allele is
Ala893, with undertransmission of the 893Ser (common) and the 893Thr (rare) variants. The Ala893 variant has
decreased activity compared with the 893Ser variant; therefore, the association with human IBD is consistent with
the murine model of mdr1 deficiency. Taken together, these data support the association of the common Ala893
polymorphism with IBD specifically and, more broadly, provides additional support for its contribution to inter-
individual pharmacogenetic variation.
Introduction
The idiopathic inflammatory bowel diseases (IBDs) com-
prise Crohn disease (CD [MIM 266600]) and ulcerative
colitis (UC [MIM 191390]), with both disorders involving
chronic, intermittent inflammation that responds to anti-
inflammatory agents such as corticosteroids and im-
munosuppressive therapies (Podolsky 2002). The dis-
tinction between UC and CD is based largely on the
distribution of inflammation; the inflammation of UC
invariably involves the rectum and extends, to a variable
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extent, proximally throughout the colon in a symmetric,
continuous manner and affects only the innermost layers
of the colonic wall. In contrast, the inflammation of CD
can affect any portion of the gastrointestinal tract, with
involvement of the terminal ileum of the small intestine
being the most commonly affected portion. Inflamma-
tion in CD is often patchy, asymmetric, and discontin-
uous in nature (where intensely involved regions are sep-
arated by uninvolved, “skip” regions) and can involve
all layers of the bowel wall. Aggressive transmural in-
volvement in CD accounts for complications involving
intestinal perforation, fistulous connections between in-
testine and/or adjacent tissues, and intestinal obstruc-
tions from strictures.
That genetic factors contribute to CD and UC patho-
genesis is indicated by the consistent findings between
studies that MZ twin concordance is significantly higher
than DZ twin concordance (Tysk et al. 1988; Thompson
et al. 1996; Subhani 1998). For CD, MZ twin concor-
dance rates are 42%–58%, whereas, for UC, estimated
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concordance has a range of 6%–17%. The relative risk
to first-degree relatives of a proband with IBD of de-
veloping the same disease is 4–10-fold (Orholm et al.
1991; Peeters et al. 1996). Furthermore, among families
having multiple members with IBD, 25% are mixed—
that is, they have members with CD as well as members
with UC (Binder 1998). Taken together, these data are
consistent with a model in which some risk alleles and/
or susceptibility genes will be common to both disorders,
whereas other susceptibility genes will be unique to ei-
ther CD or UC.
A number of genomewide searches for IBD suscepti-
bility loci have been published, and, as with other multi-
genic disorders, initially reported linkages have been var-
iably observed in subsequent studies (Hugot et al. 1996;
Satsangi et al. 1996; Cho et al. 1998; Hampe et al. 1999;
Ma et al. 1999; Duerr et al. 2000; Rioux et al. 2000;
Williams et al. 2002; Paavola-Sakki et al. 2003). Fur-
thermore, some loci have been linked primarily with CD
or UC, whereas, for other loci, linkage has been observed
in both IBD subsets. The best example of a CD-specific
locus is IBD1 in the pericentromeric region of chromo-
some 16 (Hugot et al. 1996), which is now known to be
partially due to the presence of three major coding region
polymorphisms in NOD2/CARD15 (Hugot et al. 2001;
Ogura et al. 2001). These mutations decrease innate im-
mune responsiveness (Bonen et al. 2003) to muramyl
dipeptide (Girardin et al. 2003; Inohara et al. 2003), a
minimally active component of peptidoglycan found in
the cell walls of gram-positive and -negative bacteria.
Suggestive evidence for linkage at chromosome 7q near
D7S669 was initially reported in a European cohort con-
sisting of 186 affected sibling pairs from 160 families
(Satsangi et al. 1996). Subsequent studies demonstrated
nominal evidence for linkage in this region, including
our genomewide screen (Cho et al. 1998), which dem-
onstrated nominal evidence for linkage in all families
with IBD and, in particular, among mixed families (con-
taining both CD- and UC-affected members) (maximal
multipoint LOD p 1.18).
Contained within this linkage region on chromosome
7q is the multidrug resistance 1 gene (MDR1 or ATP-
binding cassette subfamily B member 1, ABCB1 [MIM
171050]). The MDR1 gene product, P-glycoprotein-1
(PGP), was initially observed as a transport protein in-
creased in tumors developing resistance to chemothera-
peutic agents, resulting from PGP-mediated efflux of
drug from tumor cells (Choi et al. 1988). Others pro-
posed that PGP functions as a “flippase”—as opposed
to an efflux pump—moving amphipathic substrates from
the inner leaflet to the outer leaflet of the cell membrane,
with the ability to move these substrates prior to their
penetration into the cytoplasm (Higgins and Gottesman
1992; van Helvoort et al. 1996). PGP is a 12-trans-
membrane–spanning ATP-binding transporter of lipo-
philic molecules (including some chemotherapeutic
agents) across plasma membranes (Ueda et al. 1987;
Jones and George 1998). Variation in MDR1 expression
and/or genotypes has been related to altered pharma-
cokinetics of a wide range of drugs, including cortico-
steroids (Schinkel et al. 1995; Lown et al. 1997; Farrell
et al. 2000), immunosuppressives (Lown et al. 1997;
Yamauchi et al. 2002), digoxin (Hoffmeyer et al. 2000;
Kim et al. 2001; Johne et al. 2002; Verstuyft et al. 2003),
antihistamines (fexofenadine) (Kim et al. 2001), and
anticonvulsants (Siddiqui et al. 2003). Because MDR1
is broadly expressed, alterations in MDR1 expression
and activity may result in altered intestinal absorption
(Lown et al. 1997; Sparreboom et al. 1997; Hoffmeyer
et al. 2000; Kim et al. 2001), leukocyte transport (Hitzl
et al. 2001; Calado et al. 2002), blood-brain barrier
function (Schinkel et al. 1995, 1996; Furuno et al. 2002;
Yamauchi et al. 2002; Siddiqui et al. 2003), and urinary
excretion (Schinkel et al. 1995).
It is significant that, although developmentally nor-
mal, mdr1-deficient mice spontaneously develop colitis
(Schinkel et al. 1997). This suggests that functional poly-
morphisms within mdr1, which result in a loss of or
decrease in PGP activity, might increase susceptibility to
IBD (Panwala et al. 1998). Among germline polymor-
phisms within MDR1, there has been some controversy
regarding the functional significance of a missense poly-
morphism contained within exon 21 (G2677T/C-
Ala893Ser/Thr) and of a wobble polymorphism con-
tained within exon 26 (C3435T-Ile1145Ile). Various
reports have suggested that one or the other are asso-
ciated with altered transporter and/or gene-expression
activity (Hoffmeyer et al. 2000; Hitzl et al. 2001; Kim
et al. 2001; Calado et al. 2002; Johne et al. 2002; Sieg-
mund et al. 2002; Yamauchi et al. 2002; Verstuyft et
al. 2003). Recently, in a case-control study, the 3435T
variant was found to be significantly associated with
UC but not with CD (Schwab et al. 2003). Of note,
however, the Ala893Ser/Thr polymorphism was not ex-
amined in that study. In this article, we examine the
Asn21Asp variant, as well as functionally associated
polymorphisms on Ala893Ser/Thr and C3435T. We ob-
serve significant evidence for CD association for the
Ala893 variant, which has been associated with de-
creased activity relative to the 893Ser variant (Kim et
al. 2001). Furthermore, we observe no evidence for UC
or CD association for the 3435T variant.
Material and Methods
Family Ascertainment
In all cases, informed consent was obtained for mo-
lecular genetics studies approved by the institutional re-
view boards at Johns Hopkins University, University of
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Table 1
Structure of IBD Pedigrees Genotyped
PEDIGREE STRUCTURE
NO. WITH AFFECTION STATUS
IBD CD UC
Familiesa 329 264 84
Affected individualsb 558 409 119
Trios 444 353 88
Simple trio pedigreesc: 223 189 71
Non-Jewish 146 121 47
Jewish 73 64 24
Sibling pair pedigreesd: 86 62 10
Non-Jewish 51 38 5
Jewish 35 24 5
Extended pedigreese: 20 13 3
Non-Jewish 14 9 2
Jewish 6 4 1
a Twenty-two families with IBD had offspring with both UC
and CD; the offspring with UC and CD were also analyzed
separately with the other pedigrees that had offspring with only
UC and CD, respectively. Three families had offspring with only
indeterminate colitis and were included in the IBD analyses but
not in the CD or UC analyses.
b The number of affected individuals listed for families with
offspring with CD include only pedigree members with CD; the
number of affected individuals listed for families with offspring
with UC include only pedigree members with UC. Affected par-
ents are also included.
c Includes three simple trio pedigrees with indeterminate co-
litis. Because of the presence of multiple mixed sibling pair and
mixed extended pedigrees, the total number of simple trio pedi-
grees with IBD is less than the total number of simple trio pedi-
grees with CD and UC. Four trio pedigrees with CD were un-
known for Jewish ethnicity.
d The CD analyses include 4 pedigrees with CD with 3 affected
siblings, 2 pedigrees with CD with 4 affected siblings, and 18
mixed pedigrees (16 having one sibling pair with CD and one
sibling pair with UC, 1 mixed pedigree composed of two siblings
with CD and two siblings with UC, and 1 mixed pedigree com-
posed of two siblings with CD and one sibling with UC).
e Pedigrees with more than one trio and containing one or
more affected cousin pairs, avuncular pairs, or DNA samples
from three generations with parent-child pairs.
Pittsburgh, and University of Chicago Hospitals. Diag-
noses were confirmed by review of primary medical re-
cords, including radiologic, endoscopic, and pathology
reports. Table 1 summarizes the families genotyped by
diagnosis, ethnicity, and family structure. At least one
completely informative trio was available for each of the
families included in the study. A total of 329 families with
IBD was genotyped, with 35% of families of Ashkenazi
Jewish ancestry and 4 families with Jewish ethnicity status
unknown. In all, 1,188 subjects were genotyped, in-
cluding 558 subjects with IBD. For the case-control analy-
sis, 392 non-Jewish and 219 white Ashkenazi Jewish
healthy control individuals of European ancestry were
genotyped. These control individuals were ascertained
from Johns Hopkins University, the University of Chi-
cago, and (for additional Ashkenazi Jewish control in-
dividuals) a population-based cohort study. (The New
York Cancer Project control subjects are healthy indi-
viduals, randomly ascertained for longitudinal follow up
for future development of cancer.)
SNP Genotyping
Table 2 summarizes the rs designation, amino acid and
nucleotide changes, and exon locations for the three typed
SNPs. The Ala893Ser/Thr polymorphism was genotyped
by PCR sequencing (forward primer: 5′-CTGATAAAAT-
AATGAATATAGTCTC-3′; reverse primer: 5′-TAGAGC-
ATAGTAAGCAGTAGG-3′) by use of dye-terminator
chemistry (ABI3700 sequencer) and pyrosequencing (PSQ
HS96A system) (forward primer: 5′Biotin-TEG-GAGCA-
TAGTAAGCAGTAGGGA-3′; reverse primer: 5′-TACC-
CATCATTGCAATAGC-3′; pyrosequencing primer: 5′-
GATAAGAAAGAACTAGAAGG-3′). The Asn21Asp
(forward primer: 5′-ATGGAGGAGCAAAGAAGAAG-
AACTT-3′; reverse primer: 5′-CGCAACTATGTAAAC-
TATGAAAATGAAAC-3′; VIC [WT probe]: 5′-AACTG-
AACAATAAAAGG-3′; FAM [rare probe]: 5′-CTGAAC-
GATAAAAGG-3′) and C3435T polymorphisms (forward
primer: 5′-AACAGCCGGGTGGTGTCA-3′; reverse
primer: 5′-ATGTATGTTGGCCTCCTTTGCT-3′; VIC
[WT probe]: 5′-CTCACGATCTCTTC-3′; FAM [rare
probe]: 5′-CCTCACAATCTCTT-3′) were genotyped us-
ing Taqman amplification and were detected using the
ABI Prism 7700 Sequence Detection System.
Analysis
The data were checked for Mendelian inconsistencies,
and the files were prepared using the Sib-Pair program
(Duffy 1997). The same program was used to check for
deviation from Hardy-Weinberg equilibrium. For the
case-control analysis, one random affected individual of
either known white European or Ashkenazi Jewish an-
cestry was selected from each family. A similar propor-
tion of ethnically matched control subjects was geno-
typed for comparisons. The differences in allele and geno-
type frequency between two independent samples (sub-
jects vs. control individuals and Jewish control individuals
vs. white non-Jewish control individuals) were tested us-
ing x2 statistics for two-way tables. The combined white
non-Jewish and Jewish test statistic was calculated as the
sum of the individual x2 statistics. The P values were
obtained using Monte Carlo simulation.
Association analyses were performed using a pedigree-
based transmission/disequilibrium test (PDT) (Martin et
al. 2000). This program allows for inclusion of triads,
as well as extended families, in the analysis, while ad-
justing for their nonindependence. The PDT is a powerful
analytical method that utilizes genetic data from related
nuclear families and discordant sibships within extended
pedigrees. It has two global scores: the “sumPDT,” which
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Table 2
Allele Frequencies for Three MDR1 Polymorphisms in Control Individuals and Patients with IBD, Stratified by Jewish Ethnicity
rs Designation
and Amino Acid Nucleotide Exon
White Non-Jewish
Subjects with IBD
(%)
White Non-Jewish
Control Individuals
(%)
Jewish Subjects
with IBD
(%)
Jewish Control
Individuals
(%)
Pending:
Asn21 A61 2 91.3 89.1 96.4 96.3
21Asp 61G 2 8.7 10.9 3.6 3.7
rs2032582:
Ala893 G2677 21 60.2 52.4 62.7 60.5
893Ser 2677T 21 39.3 45.0 36.8 36.5
893Thr 2677A 21 .5 2.6 .4 3.0
rs1045642:
Synonymous C3435 26 50.0 45.4 57.7 64.3
Synonymous 3435T 26 50.0 54.6 42.3 35.7
summarizes the level of significance from all families,
and the “avePDT,” for which the contribution of large
families to the end result does not exceed that of the
small families. Distortion of transmission from parents
to offspring is assessed by an observed/expected x2 test.
The analysis was performed for the general phenotype
of IBD and then separately for CD and UC. The r2 link-
age disequilibrium value for SNP pairs was estimated us-
ing the method of Weir (1996). Transmission/disequilib-
rium test (TDT) and haplotype analysis were performed
using Genehunter, version 2.1 (Kruglyak et al. 1996; Kong
and Cox 1997; Markianos et al. 2001).
Results
Resequencing of MDR1 Exons
We determined the sequence of all 27 MDR1-coding
exons in DNA samples from 18 independent patients
with IBD. These patients were all probands from the 18
multiply IBD-affected pedigrees who demonstrated the
strongest evidence for linkage on chromosome 7q21.1
(at the MDR1 map location between markers D7S2204
and D7S820) in our IBD genomewide screen reported
elsewhere (Cho et al. 1998). We identified four exonic
SNPs: in exon 2 (A61G-Asn21Asp), exon 12 (C1236T),
exon 21 (G2677T/A-Ala893Ser/Thr), and exon 26
(C3435T) (table 2). We also identified two SNPs in flank-
ing introns 6 and 17. Of note is that Ala893Ser/Thr is
a triallelic amino acid polymorphism that results either
in the common alanine or serine variants or in the least
common threonine residue. The Ala893 and 893Thr exon
21 allelic variants were found only on the background
of the more common Asn21 exon 2 variant and not on
the 21Asp variant.
Because the Ala893Ser/Thr and C3435T polymor-
phisms have been associated with altered MDR1 function,
and because the Asn21Asp polymorphism represents a
nonconserved amino acid variation that could potentially
alter function, we typed these variants in a large cohort
of patients with IBD to test for disease association.
Case-Control Analysis Demonstrates Association
of Ala893 to IBD
Table 2 lists the allele frequencies for the typed mark-
ers in white non-Jewish and Jewish cohorts. For the
Asn21Asp variant, no evidence for IBD association was
observed ( ). For the C3435T polymorphism,Pp .36
marked differences in the C3435 allele frequencies were
observed between white non-Jewish (45.4%) and Jewish
(64.3%) control individuals ( ). No evi-16Pp 2.2# 10
dence for IBD association was observed for this poly-
morphism in either cohort, with an increase of the C3435
allele in the non-Jewish cohort and a decrease of the
C3435 allele in the Jewish cohort.
For the Ala893Ser/Thr variant, the Ala893 variant was
modestly increased in Jewish control individuals, as com-
pared with non-Jewish control individuals, with a re-
spective decrease in the 893Ser variant and a similar pres-
ence of the relatively rare 893Thr variant. The global
difference in allele frequencies between Jewish and non-
Jewish control individuals for Ala893Ser/Thr is modestly
significant ( ). It is important that the Ala893Pp .015
allele was increased in both white non-Jewish and Jewish
subjects with IBD, as compared with their ethnically
matched control individuals. Table 3 lists the allele and
genotype counts for the Ala893Ser/Thr variants in white
non-Jewish and Jewish cohorts. While counting alleles,
we observed significant association for Ala893Ser/Thr
for white non-Jewish subjects with IBD ( ) andPp .003
a modest trend for association among Jewish subjects
with IBD ( ). The combined significance in bothPp .09
cohorts (calculated as the sum of the individual statistics)
was . There were no significant differences be-Pp .002
tween CD Ala893 and UC allele frequencies in white
non-Jewish (60.9% vs. 61.7%, respectively) and Jewish
(63.8% vs. 64.5%, respectively) cohorts. However, be-
cause the number of UC cases is small, we would have
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Table 3
Allele and Genotype Counts for Control Individuals and Patients with IBD, Stratified by Ethnicity
ALLELE OR GENOTYPE
NO. OF
White Non-Jewish
Subjects with IBD
White Non-Jewish
Control Individuals
Jewish Subjects
with IBD
Jewish Control
Individuals
Allele:
Ala893 254 411 143 265
893Ser 166 353 84 160
893Thr 2 20 1 13
Genotype:
Ala893-Ala893 76 108 41 85
Ala893-893Ser 101 183 60 89
893Ser-893Ser 32 81 12 32
Ala893-893Thr 1 12 1 6
893Ser-893Thr 1 8 0 7
NOTE.—Differences between subjects and control individuals in each cohort were tested using the x2 statistics for
two-way tables, with significance estimates obtained by Monte Carlo simulation. For alleles and genotypes, significant
association was observed for Ala893Ser/Thr for white non-Jewish subjects with IBD ( and , respec-Pp .003 Pp .015
tively), and a modest trend for association was observed among Jewish subjects with IBD ( and ,Pp .09 Pp .072
respectively). The combined analysis of the two ethnic groups (calculated as the sum of the individual cohort statistics)
was for alleles and was for genotypes.Pp .002 Pp .008
Table 4
Global P Values by PDT Analysis of Exonic SNPs
SNP
GLOBAL P FOR PDT ANALYSIS FOR
CD UC IBD
Sum Average Sum Average Sum Average
Asn21Asp .24 .15 .26 .56 .8 .39
Ala893Ser/Thr .0014 .00090 .29 .16 .00030 .00020
C3435T .42 .31 .93 .60 .63 .35
limited power to identify modest differences. More gen-
erally, the marked allele frequency differences in MDR1
variants in various populations highlight the difficulty
of appropriately controlling for cryptic population sub-
structure in the case-control–study design. In addition,
haplotype analysis might provide further insight into the
relationship between the MDR1 variants under investi-
gation. The following sections summarize the results from
family-based association studies.
Significant Association of IBD and CD
with the Ala893Ser/Thr Polymorphism
by Family-Based Association Studies
Because the TDT is a test of both association and link-
age, in a cohort such as ours with a large number of
families with more than one affected member, the signifi-
cance values obtained by TDT do not reflect disease as-
sociation solely. A conservative correction would be to
randomly select one IBD-affected individual from each
family. Using this approach, we observed significant as-
sociation of Ala893 to IBD in all families with IBD (165
transmissions, 119 nontransmissions; ;2x p 7.45 Pp
) and in white non-Jewish families (112 transmis-.0063
sions, 79 nontransmissions; ; ) but not2x p 5.7 Pp .017
in Jewish families (53 transmissions, 40 nontransmis-
sions; ; ). These results nicely mirror2x p 1.82 Pp .18
the cohort differences observed by case-control study
(table 2), where a greater Ala893 allele-frequency dif-
ference was observed for white non-Jewish subjects with
IBD (60.2% vs. 52.4% in subjects and control individ-
uals, respectively) compared with Jewish IBD (62.7%
vs. 60.5%). Also similar to the case-control findings, we
observed marked undertransmission of the 893Thr allele
in both Jewish (zero transmissions, six nontransmissions)
and white non-Jewish (two transmissions, sevennontrans-
missions) when randomly selecting one IBD-affected sub-
ject per family.
A more powerful test of association in a cohort such
as ours is the PDT (Martin et al. 2000), which utilizes
genetic data from related nuclear families and discordant
sibships within extended pedigrees. Table 4 demon-
strates the results by PDT for the Asn21Asp, Ala893Ser/
Thr, and C3435T polymorphisms among patients with
CD, UC, and IBD. These PDT values represent trans-
mission disequilibrium independent from linkage. For the
entire cohort with IBD, significant evidence for associa-
tion was observed for the Ala893Ser/Thr polymorphism
( ), and no evidence was observedPp .00020–.00030
for the Asn21Asp or C3435T polymorphisms. Separate
evaluation by CD and UC phenotypes showed no evi-
dence of a CD association for the Asn21Asp or the
C3435T polymorphisms. In contrast, significant CD as-
sociation was observed by PDT for the Ala893Ser/Thr
polymorphism ( ). Similar but nonsig-Pp .00090–.0014
nificant trends are observed in UC for the Ala893Ser/
Thr polymorphism ( ). Because the numberPp .16–.29
of subjects with UC is significantly smaller than the num-
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Table 5
PDT Analysis of the Tri-Allelic Exon 21 SNP
ALLELE TRANSMISSION
P FOR PDT ANALYSIS FOR
CD UC IBD
Sum Average Sum Average Sum Average
Ala893 Overtransmitted .0072 .0040 .31 .15 .0021 .0010
893Ser Undertransmitted .036 .028 .43 .23 .016 .0093
893Thr Undertransmitted .0046 .0046 .16 .16 .0025 .0032
Global score .0014 .00090 .29 .16 .00030 .00020
Table 6
Linkage Disequilibrium Values
SNP Pair r2
Asn21Asp and Ala893Ser/Thr .10
Ala893Ser/Thr and C3435T .52
Asn21Asp and C3435T .09
ber of subjects with CD in this cohort, these trends do
not support a significant association of the Ala893Ser/
Thr polymorphism with UC. In the cohort with UC, in
contrast to a prior case-control study (Schwab et al.
2003), we observed no evidence for association with the
3435T polymorphism, nor was evidence observed for the
Asn21Asp.
For diallelic SNPs, the global PDT significance esti-
mates equal that for each of the variants individually. In
contrast, for triallelic SNPs, the global PDT estimates
comprise unique contributions from each of the three
variants. Subanalyses of each of the three (Ala893,
893Ser, and 893Thr) alleles showed that the overall
Ala893Ser/Thr associations for IBD and CD result from
significant overtransmissions of the Ala893 variant and
undertransmissions of the 893Ser and 893Thr variants
(table 5).
Of note is that the least common variant, 893Thr, was
associated with marked undertransmission (counting all
transmissions: 2 transmissions, 18 nontransmissions; and
by PDT: ) to IBD-affected individuals.Pp .0025–.0032
This marked undertransmission of a rare variant provides
additional support for association of the Ala893Ser/Thr
polymorphism and IBD. Therefore, for the triallelic
Ala893Ser/Thr polymorphism, the global P value by PDT
is lower ( ) than that for any allele byPp .00020–.00030
itself.
Haplotype TDT Analysis Demonstrates No Additional
Evidence for Association beyond That Observed
for the Ala893Ser/Thr Polymorphism Alone
Table 6 lists the r2 values for each pair of typed SNP.
Because of the significant linkage disequilibrium between
Ala893Ser/Thr and C3435T, we performed haplotype
TDT (table 7) to define their relationships in this cohort.
Specifically, because the 3435T variant had been re-
ported elsewhere to be associated with UC by case-con-
trol analysis, we sought to define the relationship be-
tween Ala893Ser/Thr and C3435T variants, with respect
to the evidence for PDT association in IBD.
Two-locus–haplotype analysis of the Asn21Asp-
Ala893Ser/Thr haplotype demonstrates that the less com-
mon 21Asp variant occurs solely on the Ser893 back-
ground, which is unassociated with disease. In contrast,
the Asn21-Ala893 variant represents the associated hap-
lotype (203 transmissions, 128 nontransmissions). Pref-
erential transmission of the Ala893Ser/Thr-C3435T hap-
lotypes is observed for the Ala893 variant occurring with
either the C or T allele at C3435T (table 7). Therefore,
whereas significant evidence for IBD association is ob-
served for the Ala893 allele by itself, no association is
observed for IBD for the C3435T polymorphism by sin-
gle-point or haplotype TDT.
Discussion
Given the unique, close apposition of the distal small and
large intestine to high concentrations of potentially nox-
ious bacteria, a unifying model for genes that increase
susceptibility to IBD is that they fundamentally affect
host-environment interactions. Just as NOD2/CARD15
risk alleles result in decreased responsiveness to bacterial
cell wall products (Ogura et al. 2001; Bonen et al. 2003;
Chamaillard et al. 2003), the Ala893 variant in MDR1
has been associated with relatively decreased transporter
function (Kim et al. 2001), including potentially noxious
xenobiotics (Schinkel 1997). In the mdr1 knockout
model with spontaneously developing colitis (Panwala
et al. 1998), as with most IBD models, the inflammation
required the presence of intraluminal bacteria and could
be prevented (or treated) with oral antibiotics. Further-
more, bone marrow–chimera studies showed that mdr1
deficiency in radioresistant (e.g., intestinal epithelium)
cells—not mdr1 deficiency in hematopoietic cells—was
the critical contributing factor (Panwala et al. 1998).
By sequencing 18 individuals throughout MDR1 ex-
ons and flanking introns, we would have 195% power
to identify SNPs of5% allele frequency (Kruglyak and
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Table 7
TDT for Two-Locus Haplotypes for All Patients with IBD
HAPLOTYPE
NO. OF HAPLOTYPES
Transmitted Untransmitted
Asn21Asp–Ala893Ser/Thr:
Asn21–Thr893 2 17
Asn21–Ala893 203 128
Asn21–Ser893 131 188
21Asp–Ser893 48 51
Ala893Ser/Thr–C3435T:
893Thr–C3435 0 14
893Thr–3435T 2 2
Ala893–C3435 174 133
Ala893–3435T 69 51
893Ser–C3435 14 31
893Ser–3435T 130 158
NOTE.—Haplotypes were constructed using Genehunter,
version 2.1; all affected individuals were included.
Nickerson 2001). We observe significant evidence for
association of both CD and IBD to the Ala893 allele by
both case-control analysis and PDT. Although the trend
for association of Ala893 in the UC cohort alone is
similar to that for CD, it is likely that, because of the
significantly smaller numbers of subjects with UC, the
association was not significant. By both case-control
analysis (table 3) and TDT testing for one affected in-
dividual per family, we observe a greater association of
Ala893 in white non-Jewish, compared with Jewish, co-
horts. This reflects both the higher number of white non-
Jewish families tested and the relatively modest allele
frequency difference for Ala893 in Jewish subjects with
IBD (62.7%) compared with control subjects (60.5%).
Furthermore, the Jewish control Ala893 frequency
(60.5%) is essentially equal to that of the white non-
Jewish subjects with IBD (60.2%) (table 3). By com-
parison, in 461 German control subjects, Ala893 was
observed at a 56.4% allele frequency (Cascorbi et al.
2001). Given the higher IBD prevalence in Jews, it is
not unexpected that a common IBD risk allele would
be higher in Jewish, compared with white non-Jewish
subjects with IBD and control individuals.
These very subtle allele frequency differences between
cohorts highlight the limitations of case-control analyses
and the importance of our present family-based associ-
ation findings (table 4). Ala893Ser/Thr is triallelic (table
5). Each of the three alleles showed independent distor-
tion in transmission frequencies from that expected. It is
notable that, because the rare 893Thr variant is associ-
ated with a marked undertransmission to probands with
IBD (2 transmissions, 18 nontransmissions), the overall
positive (Ala893) and negative (893Thr, 893Ser) asso-
ciations of codon 893 to CD ( ) andPp .0014–.00090
IBD ( ) are more significant than forPp .00020–.00030
any single allele by itself.
We observed marked differences in C3435 allele fre-
quency between white non-Jewish (45.4%) and Jewish
(64.3%) control subjects ( ). These dif-16P ! 2.2# 10
ferences reflect the wide allelic variability reported in
the literature, ranging from 83% (Ghanian) to 34%
(Southwest Asians) (Ameyaw et al. 2001). Within Eu-
ropean white populations, allele frequencies for the
C3435 allele in the Portuguese, Spanish, German, and
British have a range of 43%–52% (Ameyaw et al. 2001;
Cascorbi et al. 2001; Bernal et al. 2003), consistent with
the present findings of 45.4% in white non-Jewish con-
trol subjects. Therefore, the Jewish control C3435 allele
frequency of 64.3% represents the highest reported fre-
quency for white control individuals.
In contrast to a recent study of UC (Schwab et al.
2003), we found no association by either case-control
or family-based association of the 3435T allele with UC,
CD, or IBD. In that study, the allele frequencies for
C3435 were reported for UC (43.3%), CD (53.2%),
and control (51.7%) groups and concluded that the
3435T allele was associated with UC. However, all of
these allele frequencies fall within the reported range for
European cohorts; therefore, the observed differences
might simply reflect subtle differences in population sub-
structure. Furthermore, it is somewhat counterintuitive
that a putative IBD risk allele (3435T) would have a
lower allele frequency in Jewish compared with non-
Jewish whites, given the higher disease prevalence of the
former. In UC, the number of transmissions and the
number of nontransmissions for the 3435T allele were
essentially identical (49 to 50, respectively). Similarly,
there was nonsignificant undertransmission of 3435T
(as opposed to the more expected overtransmission) for
both IBD (181 transmissions to 195 nontransmissions)
and CD (232 transmissions to 247 nontransmissions).
Codon 893 of MDR1 is located in the cytoplasmic
loop occurring after the 10th transmembrane-spanning
domain (Jones and George 1998). The Ala893 variant
has a significantly lower transporter activity, compared
with the 893Ser variant, as measured by both digoxin
efflux in stable NIH-3T3 transfectants and plasma fexo-
fenadine measurements in healthy volunteers (Kim et
al. 2001). Therefore, the Ala893 IBD association is con-
sistent with the mdr1 knockout colitis model (Panwala
et al. 1998). Given the marked undertransmission of the
rare 893Thr variant, it will be of great interest to de-
termine whether our observed protective association of
this variant with IBD is secondary to higher transporter
activity in NIH-3T3 transfectants, compared with the
Ala893 variant. Because both serine and threonine resi-
dues are phosphorylated by a common group of kinases,
it may be speculated that common mechanisms of phos-
phorylation of the 893Ser and 893Thr residues might
account for increased transporter activity relative to the
Ala893 variant, thereby increasing IBD risk. Whereas
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regulation of activity has been reported to occur through
phosphorylation of various residues of PGP (Chambers
et al. 1993; Hardy et al. 1995; Germann et al. 1996), to
our knowledge, no specific instances of phosphorylation
of codon 893 have been reported; however, no groups
have explicitly addressed possible allele-specific phos-
phorylation at this codon. A third possibility for expla-
nation of the association of the Ala893 variant may be
that this amino acid change alters specific substrate bind-
ing of potential toxins or other chemicals that may affect
cellular stability or susceptibility to developing chronic
unregulated inflammation. Such an alteration could be
quite specific and unrelated to the transport activity of
each variant with regard to the substrates, such as digoxin
and fexofenadine, which have been tested in vitro.
The relationship of the Ala893Ser/Thr and C3435T
polymorphisms to overall MDR1 expression and activ-
ity is controversial. In general, MDR1 transcript ex-
pression in the intestine and activity in human subjects
has been more closely associated with the C3435T poly-
morphisms than with Ala893Ser/Thr polymorphisms.
Using quantitative immunohistochemistry and western
blot analysis, Hoffmeyer et al. (2000) evaluated intes-
tinal PGP expression in intestinal biopsies from human
volunteers. In addition, the plasma concentrations of
orally administered digoxin, a PGP substrate, were re-
corded at specific time intervals to ascertain PGP activ-
ity. This study demonstrated increased intestinal expres-
sion and activity of PGP for C3435 homozygotes as
compared with 3435T homozygotes. This study did not
evaluate the Ala893Ser/Thr polymorphisms. Consistent
with these findings, Johne et al. (2002) observed that
3435T-containing haplotypes had the greatest plasma
digoxin concentrations, consistent with lowest PGP ac-
tivity, regardless of the exon 21 genotype (Johne et al.
2002). In contrast, Nakamura et al. (2002) observed
the opposite associations of mRNA expression levels in
the duodenal enterocytes of Japanese subjects; that is,
mRNA levels isolated from enterocytes of 3435T sub-
jects were increased, compared with 3435C subjects
(Nakamura et al. 2002). Population discrepancies be-
tween the MDR1 expression studies, combined with the
fact that the C3435T polymorphism is not within a
known regulatory expression element, suggests that the
C3435T polymorphism is in linkage disequilibrium with
unknown regulatory polymorphism(s) directly influenc-
ing MDR1 expression. Differing patterns of linkage dis-
equilibrium in different populations could explain the
different findings among these studies. In contrast, Kim
et al. (2001), using the PGP substrate fexofenadine, ob-
served that 3435T homozygotes and 893Ser homozy-
gotes had increased net MDR1 transport activity (as re-
flected by relatively lower fexofenadine plasma levels)
compared with C3435 homozygotes or Ala893 homo-
zygotes. These studies all assume a direct correlation
between plasma drug levels and PGP activities. However,
plasma levels likely reflect complex, unique pharmaco-
kinetics of the absorption, distribution, and elimination
for individual drugs. When the Ala893 and 893Ser vari-
ants were expressed in stable NIH-3T3 cells (isolating
the effect of protein sequence from protein-expression
levels and eliminating the complexity of drug pharmaco-
kinetics), the Ala893 variant demonstrated lower trans-
port activity (Kim et al. 2001). A model that may rec-
oncile these diverse findings is as follows: the C3435T
polymorphism is in linkage disequilibrium with a poly-
morphism that influences MDR1 expression, whereas the
Ala893Ser/Thr polymorphism influences innate PGP ac-
tivity, perhaps in a substrate-specific or phosphorylation-
dependent fashion.
Given the pharmacogenetic significance of MDR1
combined with its importance in mediating intestinal
epithelial homeostasis, as demonstrated in the mdr1-
deficient mice (Panwala et al. 1998), additional studies
to confirm a direct, causative role of the codon 893 vari-
ants in IBD should be performed. Replication in inde-
pendent, large cohorts with IBD would be of primary
importance. Because of the large size of the present co-
hort, highly significant association is observed, but the
overall difference in association between the Ala893 and
893Ser variants, as measured by the ratios of transmis-
sion to nontransmission, is rather modest. Modest dif-
ferences in common polymorphisms demonstrating
slight functional effects probably represent the mainstay
of risk alleles for complex, multigenic disorders. More
marked association effects for the Ala893Ser/Thr poly-
morphism may eventually be observed, as additional risk
alleles/susceptibility genes acting along the same patho-
genetic pathway are identified. Such stratified analyses
should not be performed randomly for all previously
reported associations for a given disorder; rather, they
should be grounded in a plausible model that is based
on established mechanistic pathways. The marked non-
transmission of the 893Thr variant is important, since
it may be considered to be a highly significant, albeit
rare, “protective” allele against developing IBD. Greater
understanding of the endogenous substrates absorbed
and/or excreted by intestinal epithelial cells harboring
MDR1 transporters may provide important insight into
the pathogenesis and treatment of IBD.
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